J. Nixon

发表

Isoenzyme specificity of bisindolylmaleimides, selective inhibitors of protein kinase C.

P. Parker, S. Wilkinson, J. Nixon, 1993, The Biochemical journal.

A novel conformationally restricted protein kinase C inhibitor, Ro 31‐8425, inhibits human neutrophil superoxide generation by soluble, particulate and post‐receptor stimuli

P. Davis, M. Dale, B. Twomey, 1991, FEBS letters.

K252a is a potent and selective inhibitor of phosphorylase kinase.

P. Davis, S. Wilkinson, G. Lawton, 1990, Biochemical and biophysical research communications.

Novel, potent and selective inhibitors of protein kinase C show oral anti-inflammatory activity.

E. J. Lewis, J. Bishop, P. Davis, 1991, Drugs under experimental and clinical research.

The design and biological properties of potent and selective inhibitors of protein kinase C.

E. J. Lewis, J. Bishop, P. Davis, 1992, Biochemical Society transactions.

FKBP, thought to be identical to PKCI-2, does not inhibit protein kinase C

Jun S. Liu, S. Schreiber, M. Albers, 1991 .

Biological Properties of the Angiotensin-Converting Enzyme Inhibitor Cilazapril

I. L. Natoff, J. Nixon, E. Worth, 1985, Journal of cardiovascular pharmacology.

Inhibition of bovine nasal cartilage degradation by selective matrix metalloproteinase inhibitors.

N. Borkakoti, P. Eyers, T. Hallam, 1997, The Biochemical journal.

Metalloproteinase inhibitors: new opportunities for the treatment of rheumatoid arthritis and osteoarthritis

T. Shaw, J. Nixon, K. Bottomley, 2000, Expert opinion on investigational drugs.

Collagenase and Family

N. Borkakoti, F. Winkler, A. D'arcy, 1998 .

Ro 32‐3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo

J. Bishop, E. J. Lewis, B. Sutton, 1997, British journal of pharmacology.

Targets for Drug Design

N. Borkakoti, F. Winkler, E. J. Lewis, 1998 .

Different sensitivities of neutrophil responses to a selective protein kinase C inhibitor Ro 31-8425; redundancy in signal transduction.

J. Merritt, S. Wilkinson, J. Tse, 1997, Cellular signalling.

The effect of new potent selective inhibitors of protein kinase C on the neutrophil respiratory burst.

M. Dale, B. Twomey, S. Wilkinson, 1990, Biochemical and biophysical research communications.

Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain.

Janet L. Smith, D. Vesey, P. Davis, 1994 .

Design and synthesis of the cartilage protective agent (CPA, Ro32-3555)

N. Borkakoti, M. Cooper, E. J. Lewis, 1997 .

Potent selective inhibitors of protein kinase C

P. Davis, S. Wilkinson, G. Lawton, 1989, FEBS letters.

Inhibitors of protein kinase C. 3. Potent and highly selective bisindolylmaleimides by conformational restriction.

D. Vesey, P. Davis, P D Davis, 1993, Journal of medicinal chemistry.

Inhibitors of protein kinase C. 2. Substituted bisindolylmaleimides with improved potency and selectivity.

P. Davis, P D Davis, C H Hill, 1992, Journal of medicinal chemistry.

Therapeutic potential of protein kinase C inhibitors

David Bradshaw, Sandra E. Wilkinson, S. Wilkinson, 2005, Agents and Actions.

1H-NMR and protection studies of interactions between ligands and bovine pancreatic phospholipase A2.

M. Williamson, P. Davis, J. Nixon, 1989, Biochimica et biophysica acta.

Molecular basis of new approaches to the therapy of rheumatoid arthritis.

M. K. Kumar, E. J. Lewis, J. Nixon, 1991, Molecular aspects of medicine.

Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides.

P. Davis, P D Davis, C H Hill, 1992, Journal of medicinal chemistry.

Potent collagenase inhibitors prevent interleukin-1-induced cartilage degradation in vitro.

S. Wilkinson, G. Lawton, J. Nixon, 1991, International journal of tissue reactions.

Modulation of cellular processes by H7, a non-selective inhibitor of protein kinases

P. Davis, S. Wilkinson, J. Nixon, 1991, Agents and Actions.

New potent inhibitors of angiotensin converting enzyme

S. Redshaw, C. Hassall, G. Lawton, 1984, FEBS letters.

(E)-2(R)-[1(S)-(Hydroxycarbamoyl)-4-phenyl-3-butenyl]-2'-isobutyl-2'-(methanesulfonyl)-4-methylvalerohydrazide (Ro 32-7315), a selective and orally active inhibitor of tumor necrosis factor-alpha convertase.

J. Kneer, D. Walter, R. Devos, 2002, The Journal of pharmacology and experimental therapeutics.

Metalloproteinases as Targets for Anti-Inflammatory Drugs

D. Bradshaw, K. M. K. Bottomley, John S. Nixon, 1999, Progress in Inflammation Research.

Oral, anti-inflammatory activity of a potent, selective, protein kinase C inhibitor

P. Davis, S. Wilkinson, G. Lawton, 1992, Agents and Actions.